Antisense therapy

Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society

Retrieved on: 
Thursday, October 1, 2020
Therapeutic gene modulation, Antisense RNA, Life sciences, Biology, Spinal muscular atrophy, Genetics, Huntington's disease, Ionis Pharmaceuticals, Ionis, Antisense therapy, C. Frank Bennett

CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that Frank Bennett, Ph.D., Ionis' executive vice president and chief scientific officer, has been awarded the 2020 Lifetime Achievement Award by the Oligonucleotide Therapeutics Society (OTS).

Key Points: 
  • CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that Frank Bennett, Ph.D., Ionis' executive vice president and chief scientific officer, has been awarded the 2020 Lifetime Achievement Award by the Oligonucleotide Therapeutics Society (OTS).
  • A founding member of Ionis, Dr. Bennett is responsible for continuing to advance antisense technology and expanding Ionis' drug discovery platform.
  • He is also the franchise leader for neurological programs at Ionis.
  • "I am deeply honored and humbled to be recognized by the Oligonucleotide Therapeutics Society with the Lifetime Achievement Award.

Ionis Pharmaceuticals to hold cardio-renal franchise webcast

Retrieved on: 
Wednesday, August 26, 2020
Branches of biology, Biology, Therapeutic gene modulation, Life sciences, RNA, Molecular biology, Ionis, Sense, Ionis Pharmaceuticals, Antisense therapy

A webcast replay will be available for a limited time at the same address.

Key Points: 
  • A webcast replay will be available for a limited time at the same address.
  • As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.
  • Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs.
  • To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

Retrieved on: 
Tuesday, August 18, 2020
Therapeutic gene modulation, Antisense RNA, Spinal muscular atrophy, Life sciences, Huntington's disease, Ionis Pharmaceuticals, Biology, Genetics, Antisense therapy, Ionis

AKCEA-APOCIII-LRx was discovered by Ionis and has been co-developed by Akcea and Ionis.

Key Points: 
  • AKCEA-APOCIII-LRx was discovered by Ionis and has been co-developed by Akcea and Ionis.
  • Akcea and Ionis intend to pursue development in familial chylomicronemia syndrome, or FCS, and are considering pursuing development in additional indications.
  • All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology.
  • In this press release, unless the context requires otherwise, "Ionis," "Akcea," "Company," "Companies," "we," "our," and "us" refers toIonis Pharmaceuticalsand/orAkcea Therapeutics.

DGAP-News: Secarna Pharmaceuticals and Evotec form strategic partnership in the field of antisense therapy

Retrieved on: 
Wednesday, August 5, 2020
Branches of biology, Biology, Life sciences, Evotec, Therapeutic gene modulation, Antisense therapy, Sense, Oligonucleotide, TecDAX, MDAX, Secarna's proprietary drug discovery platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG, Evotec SE

Munich/Martinsried and Hamburg, Germany, August 05, 2020 - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), today announced a strategic partnership in the field of antisense oligonucleotide ("ASO")-based therapeutics.

Key Points: 
  • Munich/Martinsried and Hamburg, Germany, August 05, 2020 - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), today announced a strategic partnership in the field of antisense oligonucleotide ("ASO")-based therapeutics.
  • Using state-of-the-art bioinformatics (OligofyerTM), Secarna's antisense molecules are precisely engineered to specifically bind to the targeted RNA of the gene of interest.
  • With their framework agreement, Evotec and Secarna have laid the foundation for a long-term platform collaboration spanning across a number of targets and indications.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "This strategic partnership with Secarna further complements Evotec's multimodality platform.

DGAP-News: EVOTEC AND SECARNA PHARMACEUTICALS FORM STRATEGIC PARTNERSHIP IN THE FIELD OF ANTISENSE THERAPY

Retrieved on: 
Wednesday, August 5, 2020
Branches of biology, Biology, Life sciences, Therapeutic gene modulation, Evotec, Applied genetics, Biotechnology, Antisense therapy, Molecular biology, MDAX, Sense, TecDAX

Hamburg and Marburg, Germany, 05 August 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), today announced a strategic partnership in the field of antisense oligonucleotide ("ASO")-based therapeutics.

Key Points: 
  • Hamburg and Marburg, Germany, 05 August 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), today announced a strategic partnership in the field of antisense oligonucleotide ("ASO")-based therapeutics.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "This strategic partnership with Secarna further complements Evotec's multimodality platform.
  • Antisense therapy is a form of treatment for a broad range of indications such as genetic disorders or infections.
  • ABOUT SECARNA PHARMACEUTICALS GMBH & CO. KG
    Secarna Pharmaceuticals is the leading independent European antisense drug discovery company.

NeuBase Therapeutics to Present at the BTIG Virtual Biotechnology Conference on Tuesday, August 11th

Retrieved on: 
Thursday, July 30, 2020
Branches of biology, Biology, Molecular biology, DNA, RNA, Nucleic acids, Biotechnology, Sense, Oligonucleotide, Gene silencing, Antisense therapy, Peptide nucleic acid

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

Key Points: 
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
  • The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures.
  • Using PATrOL technology, NeuBase aims to first tackle rare, genetic diseases.

MATEON AND GMP COMPLETED RESEARCH AND SERVICE AGREEMENT

Retrieved on: 
Monday, June 22, 2020
Oxygen compounds, Organic compounds, Chemical compounds, Biotechnology, Artemisinin, Commercialization of traditional medicines, Traditional Chinese medicine, Antisense therapy, OTC Markets Group

AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Mateon or the Company) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the Agreement) entered on February 3, 2020 and modified on March 22, 2020.

Key Points: 
  • AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Mateon or the Company) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the Agreement) entered on February 3, 2020 and modified on March 22, 2020.
  • GMP and Mateon are now moving forward with the clinical development of OT-101, Artemisinin, and other antisense drug candidates against SAR-CoV-2 (COVID-19).
  • GMP and Mateon are working tirelessly to ensure that OT-101 and Artemisinin prove to be safe and efficacious for patients with COVID-19.
  • In aggregate GMP has invested >$1.2M in non-dilutive funding in this project allowing us to move quickly to clinical development, said Amit Shah, CFO, Mateon Therapeutics.

Mateon and GMP Completed Research and Service Agreement

Retrieved on: 
Monday, June 22, 2020
Oxygen compounds, Organic compounds, Chemical compounds, Biotechnology, Artemisinin, Commercialization of traditional medicines, Traditional Chinese medicine, Antisense therapy, OTC Markets Group

AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Mateon or the Company) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the Agreement) entered on February 3, 2020 and modified on March 22, 2020.

Key Points: 
  • AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Mateon or the Company) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the Agreement) entered on February 3, 2020 and modified on March 22, 2020.
  • GMP and Mateon are now moving forward with the clinical development of OT-101, Artemisinin, and other antisense drug candidates against SAR-CoV-2 (COVID-19).
  • GMP and Mateon are working tirelessly to ensure that OT-101 and Artemisinin prove to be safe and efficacious for patients with COVID-19.
  • In aggregate GMP has invested >$1.2M in non-dilutive funding in this project allowing us to move quickly to clinical development, said Amit Shah, CFO, Mateon Therapeutics.

Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Retrieved on: 
Wednesday, June 17, 2020
Spinal muscular atrophy, Therapeutic gene modulation, Antisense RNA, Life sciences, Biology, Ionis, Branches of biology, Biotechnology, Antisense therapy, NASDAQ Biotechnology Index

A live webcast of the presentation will be available on the "Media & Investors" section of the Akcea website.

Key Points: 
  • A live webcast of the presentation will be available on the "Media & Investors" section of the Akcea website.
  • All six medicines were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology.
  • In this press release, unless the context requires otherwise, "Ionis," "Akcea," "Company," "Companies," "we," "our," and "us" refers toIonis Pharmaceuticalsand/orAkcea Therapeutics.
  • Ionis Pharmaceuticals is a trademark ofIonis Pharmaceuticals, Inc., Akcea Therapeutics, TEGSEDIand WAYLIVRAare trademarks ofAkcea Therapeutics, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/akcea-therapeutics-to-present-at...

Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website

Retrieved on: 
Thursday, June 11, 2020
Biotechnology, Pharmaceutical, Health, Biology, Branches of biology, Life sciences, Biotechnology, Antisense therapy, Gene therapy, Therapeutic gene modulation, RTT, Muscular Dystrophy Association, Muscular dystrophy, MDA, Dystrophy, Antisense Therapeutics, MDA

Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.

Key Points: 
  • Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.
  • The Poster can be viewed on our website at the following link: Poster Presentation Muscular Dystrophy Virtual Conference 2020
    Mark Diamond, Chief Executive Officer of Antisense Therapeutics said: Given the challenging times we are living in, MDA had to reimagine their annual conference and so have recently announced the launch of their 2020 MDA Virtual Conference Hub.
  • About Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
  • About MDA For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.